electroCore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation For Treatment Of Acute Neurological Injury Presented At 2023 World Stroke Congress
Portfolio Pulse from Benzinga Newsdesk
ElectroCore, Inc. (NASDAQ:ECOR) has announced top line data from two clinical trials presented at the 2023 World Stroke Congress. The trials suggest that non-invasive Vagus Nerve Stimulation (nVNS) is safe and effective for the treatment of acute neurological injuries. The VANQUISH trial showed a significant reduction in pain and a decrease in the use of acute pain medications, including opioids, in patients with Subarachnoid Hemorrhage. The NOVIS trial, which will complete recruitment in 2023, is studying the efficacy of nVNS in the acute treatment of Ischemic Stroke.
October 10, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ElectroCore's announcement of positive data from two clinical trials on non-invasive Vagus Nerve Stimulation could potentially boost investor confidence and the company's stock price in the short term.
The announcement of positive data from clinical trials is typically seen as a positive development for biotech companies. This could lead to increased investor confidence in ElectroCore's ability to develop effective treatments, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100